Handelsbanken Fonder AB Has $50.92 Million Stake in Bristol Myers Squibb Company $BMY

Handelsbanken Fonder AB trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 22.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,129,019 shares of the biopharmaceutical company’s stock after selling 332,506 shares during the period. Handelsbanken Fonder AB owned 0.06% of Bristol Myers Squibb worth $50,919,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BMY. Vanguard Group Inc. raised its position in shares of Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after purchasing an additional 1,058,803 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after buying an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC raised its holdings in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock worth $2,132,976,000 after acquiring an additional 723,459 shares during the period. Norges Bank acquired a new position in Bristol Myers Squibb during the 2nd quarter worth $1,554,154,000. Finally, Ameriprise Financial Inc. boosted its holdings in Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after acquiring an additional 432,158 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — the readout validates an ADC Bristol Myers licensed and could materially boost future revenue potential (deal carries >$8B long‑term economics that BMS has highlighted), which is likely the main driver lifting sentiment today. Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
• Neutral Sentiment: Coverage pieces note BMY has lagged the Nasdaq over the last year, but Wall Street remains moderately optimistic — this frames today’s rally as driven more by idiosyncratic clinical news than by broad market leadership. Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
• Neutral Sentiment: Sector updates and analyst writeups (momentum/value profiles) are highlighting BMY as a top‑ranked momentum/value/dividend candidate for different investor styles — these stories can attract additional retail and income‑oriented flows but are not major catalysts by themselves. Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
• Neutral Sentiment: General pharma‑sector coverage and updates mention BMY among large‑cap players with deep late‑stage pipelines — supportive context but not a standalone catalyst. Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target (implying slight downside versus recent levels); that cautious initiation caps upside for some investors and may limit the size of gains if broader sentiment cools. RBC Capital Initiates Bristol Myers (BMY) with $60 Target

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BMY shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Leerink Partners boosted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Scotiabank reiterated a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Finally, UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price objective for the company from $46.00 to $65.00 in a research report on Wednesday, January 7th. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $60.71.

Bristol Myers Squibb Trading Up 1.9%

Shares of Bristol Myers Squibb stock opened at $62.23 on Friday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The firm has a market capitalization of $126.74 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company’s fifty day moving average price is $56.98 and its two-hundred day moving average price is $50.52.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.